Illuminating The Pathway To Efficient Drug Development For Small Biotechs

By William Powers, Senior Director of Business Development and Marketing

As small biotech companies continue to be a driving force for innovation in the prescription drug market, CDMOs are striving to better accommodate their specific challenges. Often, these fledgling companies have limited funding and must rapidly reach new milestones to unlock additional capital. To help meet the needs of these unique clients, CDMOs must familiarize their teams with the distinct struggles, including the need for aggressive timelines, limited amounts of API, a lack of existing knowledge about the material, and no established regulatory strategy.

In drug manufacturing, every client requires their own approach. Some clients already have ample experience with their product and things go smoothly from the start. Others come with challenges around API solubility, stability, and scaleup. However, the majority of client partnerships have the potential to go either way. The determining factor? A CDMO’s ability to meet a client where they are, serve their goals, and provide enhanced project outcomes.